Monday, November 16, 2026 Never miss a recall or a rule change Get the free brief →
Inside MedSpa
FDA Recall & Compliance Alerts for Medspa Owners
Business & M&AInMode Q3 revenue holds near $92.1M, margins slip3 days agoRegulatoryJudge bars Medicare price for Botox over plasma rulelast weekRegulatoryMexico approves Restylane Shaype for jawline first3 days agoBusiness & M&AEvolus posts Q3 loss of $0.09, revenue tops estimateslast weekBusiness & M&ACoty shareholders approve 50M-share equity plan boost4 days agoMarketAllergan posts nine ASDS abstracts, two on GLP-1 patientslast weekDevices & TechConexeu's first human collagen batch meets its own specs5 days agoBusiness & M&AGalderma lifts 2026 sales outlook to 22.5-23.5%last weekBusiness & M&AMedytox Q3 operating profit up 74.5% on toxin sales5 days agoBusiness & M&ACytrellis Brings ellacor into UM Nurse Practitioner Courselast weekRegulatoryTrifluent recalls Tridacaine III lidocaine patch6 days agoRegulatoryFDA clears Shenzhen Bway red/NIR LED face mask6 days ago
Business & M&A

Medytox Q3 operating profit up 74.5% on toxin sales

Revenue slipped 2.8% in the quarter, but cost discipline and a new fat-reduction injectable carried operating profit to 15.5 billion won.

Close-up of two businessmen shaking hands, symbolizing agreement and partnership.
Photo: Bia Limova / Pexels

Get the free Inside MedSpa brief by email

The free Inside MedSpa brief · no card · unsubscribe anytime. Privacy.

South Korea's Medytox posted third-quarter operating profit of 15.5 billion won, up 74.5% from a year earlier, according to a Seoul Economic Daily report on the company's results. The story, published November 10, 2026, is built on a company statement. Revenue for the quarter was 59.3 billion won, about $41 million by the paper's conversion, and it fell 2.8%.

That gap is the story. Revenue went down while profit rose sharply. The reason is margin, not volume. The company credits better cost ratios and lower selling and administrative expenses. Net profit for the period reached 11.6 billion won, up 61.4%.

Free alerts

Free: recall & rule-change alerts for your practice.

Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.

The free Inside MedSpa brief · no card · unsubscribe anytime. Privacy.

Revenue fell 2.8% from a year earlier, while operating profit climbed 74.5%.

Where the money came from

Botulinum toxin products, Medytox's main line, brought in 35.5 billion won in the quarter. The domestic business held steady, and the source names Coretox as the South Korean product that kept sales level. Overseas revenue for the toxin lines rose 17% year on year. The company credits a dual-brand approach built on Meditoxin and Newlux. Newlux is a next-generation toxin formulation developed by affiliate Newmeco.

Nubijou is the newer piece. It is a fat-reduction injectable that contains cholic acid. The source says South Korea's Ministry of Food and Drug Safety approved it as the country's 40th domestically developed new drug. A Medytox official said the product "sped up its spread into the domestic market and hit this year's sales target early. The document gives no Nubijou revenue figure. I cannot tell you how much of the 35.5 billion won toxin total it accounts for, or whether it sits in that line at all.

The filler problem

Hyaluronic acid fillers were the weak spot. The company says that segment fell temporarily because it realigned its global sales channels. Its fix is a direct-export model that drops intermediate distributors.

For owners who buy Neuramis product, the timing matters. Medytox expects overseas filler revenue to recover from the fourth quarter, when local supply begins in earnest for two Neuramis fillers, Deep Lidocaine and Volume Lidocaine. Both received approval from China's National Medical Products Administration (NMPA). That is a Chinese regulator. It is not an FDA action. Nothing in the document speaks to U.S. status. In South Korea, the company plans to go after skin booster demand with Neuramis Skin Enhancer.

What it means for practices

Analysis: a toxin maker that grows abroad while cutting its own selling costs is telling you its distribution cost is the lever, not its price. If you carry Medytox product, expect the company to push direct. A direct-export model can mean a cleaner supply chain for buyers. It can also mean fewer local intermediaries to call when a lot is delayed. Ask your distributor which side of that change you sit on before the fourth quarter.

The consumer-side moves matter less to a clinic buyer but show where the company is putting its effort. Neuraderm is entering Olive Young and Musinsa Beauty and preparing a new Daily Essential line. Lactiplan, a probiotic the company describes as aimed at reducing body fat, is moving from pharmacies to online platforms.

What owners can do

If you stock or plan to stock Medytox toxins, ask for the current NMPA and MFDS status of any product you are considering, in writing, from the supplier. Do not rely on a Korean approval for a U.S. or other market. If you hold Neuramis filler, watch your fourth-quarter supply. The company has tied its filler recovery to that quarter, so a delay now is a signal worth raising early. If you buy Nubijou or any cholic-acid injectable, confirm the approval scope in the product literature. The source gives only a Korean approval, with no indication details beyond the fat-reduction label.

What we don't know

The document does not break out Nubijou revenue, does not say how large the overseas toxin market was in the quarter, and does not name a dollar figure for the filler decline. It gives no FDA status for any Medytox product. The company's "record revenue this year" target is a stated goal, and the quarter's 2.8% revenue drop makes it a harder bar to clear. The source is an AI-translated Korean report, so the quotes are secondhand and may not match the original wording.

Business information, not medical or legal advice. Verify regulatory status at FDA.gov.

Source: original report ↗

Business information, not medical or legal advice. Verify product status at FDA.gov.

Free alerts

Free: recall & rule-change alerts for your practice.

Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.

The free Inside MedSpa brief · no card · unsubscribe anytime. Privacy.

Share

https://insidemedspa.com/article/medytox-q3-operating-profit-up-74-percent-toxin-nubijou/

Discussion

    Leave a comment

    Comments are reviewed before they appear.
    Inside MedSpa · Free brief

    By the time it's news, it's too late.

    FDA decisions, recalls and the rules you operate under, drafted from the source documents and sent free by email.

    Get the free brief The free Inside MedSpa brief · no card · unsubscribe anytime.
    FDA, recalls and rule changes for practice owners Get the free brief →